Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2022 10:07 ET | Source: TVAX Biomedical

TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study

OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...